quinolinic acid has been researched along with Dyskinesia, Medication-Induced in 5 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinolinic acid (QUIN) was used as a typical excitotoxic/pro-oxidant inducer, 3-nitropropionic acid (3-NP) was employed as a mitochondrial function inhibitor, and their combination (QUIN + 3-NP) was also evaluated in in vitro studies." | 1.36 | Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. ( Elinos-Calderón, D; Galván-Arzate, S; Maldonado, PD; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Robledo-Arratia, Y; Santamaría, A, 2010) |
| "This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamatergic function." | 1.33 | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. ( Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gago, B | 1 |
| Marin, C | 1 |
| Rodríguez-Oroz, MC | 1 |
| Obeso, JA | 1 |
| Elinos-Calderón, D | 1 |
| Robledo-Arratia, Y | 1 |
| Pérez-De La Cruz, V | 1 |
| Maldonado, PD | 1 |
| Galván-Arzate, S | 1 |
| Pedraza-Chaverrí, J | 1 |
| Santamaría, A | 1 |
| Samadi, P | 2 |
| Grégoire, L | 2 |
| Rassoulpour, A | 2 |
| Guidetti, P | 2 |
| Izzo, E | 2 |
| Schwarcz, R | 2 |
| Bédard, PJ | 2 |
| Di Paolo, T | 1 |
| Storey, E | 1 |
| Cipolloni, PB | 1 |
| Ferrante, RJ | 1 |
| Kowall, NW | 1 |
| Beal, MF | 1 |
5 other studies available for quinolinic acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Mov | 2013 |
Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine.
Topics: Animals; Antioxidants; Brain; Corpus Striatum; Cysteine; Disease Models, Animal; Dyskinesia, Drug-In | 2010 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose- | 2005 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskines | 2008 |
Movement disorder following excitotoxin lesions in primates.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dyskinesia, Drug-I | 1994 |